Published in J Intern Med on August 20, 2012
Leveraging biospecimen resources for discovery or validation of markers for early cancer detection. J Natl Cancer Inst (2015) 0.90
Precision medicine in chronic disease management: The multiple sclerosis BioScreen. Ann Neurol (2014) 0.87
Toward rapid, high-sensitivity, volume-constrained biomarker quantification and validation using backscattering interferometry. Anal Chem (2014) 0.81
The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev (2001) 2.47
The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin Chim Acta (1995) 2.06
Resveratrol: a molecule whose time has come? And gone? Clin Biochem (1997) 1.96
Highly elevated levels of prostaglandin D synthase in the serum of patients with renal failure. Urology (1999) 1.87
Prostate-specific antigen in milk of lactating women. Clin Chem (1995) 1.79
The periurethral glands do not significantly influence the serum prostate specific antigen concentration. J Urol (1996) 1.73
Multianalyte immunoassay based on spatially distinct fluorescent areas quantified by laser-excited solid-phase time-resolved fluorometry. Clin Chem (1992) 1.61
Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer (1994) 1.53
Elevated levels of prostate-specific antigen in serum of women with fibroadenomas and breast cysts. J Natl Cancer Inst (1997) 1.50
Wine as a biological fluid: history, production, and role in disease prevention. J Clin Lab Anal (1997) 1.48
Steroid hormone regulation of prostate-specific antigen gene expression in breast cancer. Br J Cancer (1997) 1.44
CUB and zona pellucida-like domain-containing protein 1 (CUZD1): a novel serological biomarker for ovarian cancer. Clin Biochem (2012) 1.40
Prostate-specific antigen in cerebrospinal fluid. Clin Chem (1997) 1.39
Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Res (1995) 1.38
The new kallikrein-like gene, KLK-L2. Molecular characterization, mapping, tissue expression, and hormonal regulation. J Biol Chem (1999) 1.30
Immunoreactive prostate-specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age. Clin Biochem (1994) 1.29
An automated "high-pressure" liquid-chromatographic assay for hemoglobin A1c. Clin Chem (1984) 1.27
Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Res Treat (1996) 1.27
Breast and prostate cancer: an analysis of common epidemiological, genetic, and biochemical features. Endocr Rev (1998) 1.26
Quantitative analysis of macrophage inhibitory cytokine-1 (MIC-1) gene expression in human prostatic tissues. Br J Cancer (2003) 1.25
Ultrasensitive bioanalytical assays using time-resolved fluorescence detection. Pharmacol Ther (1995) 1.24
Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel. Br J Cancer (2008) 1.21
New biological functions of prostate-specific antigen? J Clin Endocrinol Metab (1995) 1.19
Wines and grape juices as modulators of platelet aggregation in healthy human subjects. Clin Chim Acta (1996) 1.15
Insulin-like growth factor-binding protein-3 and breast cancer survival. Int J Cancer (1998) 1.14
Platform for establishing interlaboratory reproducibility of selected reaction monitoring-based mass spectrometry peptide assays. J Proteome Res (2010) 1.13
Automation of molecular diagnostics. Clin Chem (1996) 1.13
Development of an ultrasensitive immunoassay for human glandular kallikrein with no cross-reactivity from prostate-specific antigen. Clin Chem (1999) 1.12
Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study. Clin Cancer Res (1998) 1.11
Detection of prostate cancer relapse with prostate specific antigen monitoring at levels of 0.001 to 0.1 microG./L. J Urol (1997) 1.11
Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue. Urology (2000) 1.10
The diagnostic and prognostic utility of prostate-specific antigen for diseases of the breast. Breast Cancer Res Treat (2000) 1.09
A new europium chelate for protein labelling and time-resolved fluorometric applications. Clin Biochem (1988) 1.08
Multiple tissue kallikrein mRNA and protein expression in normal skin and skin diseases. Br J Dermatol (2005) 1.08
Induction of prostate specific antigen production by steroids and tamoxifen in breast cancer cell lines. Breast Cancer Res Treat (1994) 1.08
Frequency of expression of prostate-specific antigen mRNA in lung tumors. Am J Clin Pathol (1997) 1.07
Steroid hormone activity of flavonoids and related compounds. Breast Cancer Res Treat (2000) 1.07
Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer. Br J Cancer (2001) 1.07
Genomic organization of the human kallikrein gene family on chromosome 19q13.3-q13.4. Biochem Biophys Res Commun (2000) 1.05
Serum total and free prostate-specific antigen for breast cancer diagnosis in women. Clin Cancer Res (2000) 1.03
Creatine kinase BB isoenzyme levels in tumour cytosols and survival of breast cancer patients. Br J Cancer (1996) 1.03
Kallikrein gene downregulation in breast cancer. Br J Cancer (2004) 1.03
Molecular cloning, physical mapping, and expression analysis of a novel gene, BCL2L12, encoding a proline-rich protein with a highly conserved BH2 domain of the Bcl-2 family. Genomics (2001) 1.02
Circulating antibodies against p53 protein in patients with ovarian carcinoma. Correlation with clinicopathologic features and survival. Cancer (1996) 1.02
Time-resolved detection of lanthanide luminescence for ultrasensitive bioanalytical assays. J Photochem Photobiol B (1995) 1.02
Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer (1995) 1.02
Genomic organization, physical mapping, and expression analysis of the human protein arginine methyltransferase 1 gene. Biochem Biophys Res Commun (2000) 1.02
Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients. Clin Cancer Res (2001) 1.00
Identification of heat shock protein 90 and other proteins as tumour antigens by serological screening of an ovarian carcinoma expression library. Br J Cancer (2002) 1.00
Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen. J Clin Oncol (2000) 1.00
Prostate-specific antigen immunoreactivity in amniotic fluid. Clin Chem (1995) 1.00
Measurement of serum prostate specific antigen levels in women and in prostatectomized men with an ultrasensitive immunoassay technique. J Urol (1995) 0.99
Ultrasensitive assay of prostate-specific antigen used for early detection of prostate cancer relapse and estimation of tumor-doubling time after radical prostatectomy. Clin Chem (1995) 0.99
Ultrasensitive time-resolved immunofluorometric assay of prostate-specific antigen in serum and preliminary clinical studies. Clin Chem (1993) 0.99
Oral contraceptive-induced expression of prostate-specific antigen in the female breast. J Biol Chem (1995) 0.98
Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer. Br J Cancer (1996) 0.98
Polyvinylamine-streptavidin complexes labeled with a europium chelator: a universal detection reagent for solid-phase time resolved fluorometric applications. Clin Biochem (2000) 0.98
Molecular cloning of the human kallikrein 15 gene (KLK15). Up-regulation in prostate cancer. J Biol Chem (2001) 0.98
Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma. Clin Cancer Res (2001) 0.98
Transcriptional upregulation of human tissue kallikrein 6 in ovarian cancer: clinical and mechanistic aspects. Br J Cancer (2007) 0.98
Prostate-specific antigen expression by various tumors. J Clin Lab Anal (1995) 0.98
Prostate-specific antigen in serum of women with breast cancer. Br J Cancer (1995) 0.98
Human kallikrein 10: a novel tumor marker for ovarian carcinoma? Clin Chim Acta (2001) 0.97
The expanded human kallikrein gene family: locus characterization and molecular cloning of a new member, KLK-L3 (KLK9). Genomics (2000) 0.97
Differential steroid hormone regulation of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) in breast cancer cell lines. Breast Cancer Res Treat (2000) 0.97
Salivary duct carcinoma secreting prostate-specific antigen. Am J Clin Pathol (1996) 0.97
The spectrum of human kallikrein 6 (zyme/protease M/neurosin) expression in human tissues as assessed by immunohistochemistry. J Histochem Cytochem (2001) 0.96
The world of resveratrol. Adv Exp Med Biol (2001) 0.96
Molecular characterization of prostate-specific antigen messenger RNA expressed in breast tumors. Cancer Res (1994) 0.96
Humoral immune response against p53 protein in patients with colorectal carcinoma. Int J Cancer (1997) 0.95
Immunofluorometric quantitation and histochemical localisation of kallikrein 6 protein in ovarian cancer tissue: a new independent unfavourable prognostic biomarker. Br J Cancer (2002) 0.95
Identification of novel human kallikrein-like genes on chromosome 19q13.3-q13.4. Anticancer Res (2000) 0.95
Health aspects of partially defatted flaxseed, including effects on serum lipids, oxidative measures, and ex vivo androgen and progestin activity: a controlled crossover trial. Am J Clin Nutr (1999) 0.94
Expression of the prostate-specific antigen gene by a primary ovarian carcinoma. Cancer Res (1995) 0.94
The human KLK8 (neuropsin/ovasin) gene: identification of two novel splice variants and its prognostic value in ovarian cancer. Clin Cancer Res (2001) 0.94
Absorption of trans-resveratrol in rats. Methods Enzymol (2001) 0.94
Prostate-specific antigen in female serum, a potential new marker of androgen excess. J Clin Endocrinol Metab (1997) 0.94
Enzymatically amplified time-resolved fluorescence immunoassay with terbium chelates. Anal Chem (1992) 0.93
Clinical utility of kallikrein-related peptidases (KLK) in urogenital malignancies. Thromb Haemost (2013) 0.92
Proteomic patterns in serum and identification of ovarian cancer. Lancet (2002) 0.92
KLK12 is a novel serine protease and a new member of the human kallikrein gene family-differential expression in breast cancer. Genomics (2000) 0.91
Immunological quantification of advanced glycosylation end-products in the serum of patients on hemodialysis or CAPD. Kidney Int (1994) 0.91
Quantification of p53 protein in tumor cell lines, breast tissue extracts and serum with time-resolved immunofluorometry. Oncogene (1993) 0.90
Identification and characterization of KLK-L4, a new kallikrein-like gene that appears to be down-regulated in breast cancer tissues. J Biol Chem (2000) 0.90
Streptavidin-polyvinylamine conjugates labeled with a europium chelate: applications in immunoassay, immunohistochemistry, and microarrays. Clin Chem (2000) 0.89
Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker. Cancer Res (2001) 0.89
Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer. Br J Cancer (1999) 0.89
Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance. Br J Cancer (2002) 0.89
Digoxin immunoassay with monoclonal and polyclonal antibodies using time-resolved fluorometry. J Pharm Sci (1989) 0.89
Prostate specific antigen molecular forms in breast cyst fluid and serum of women with fibrocystic breast disease. J Clin Lab Anal (1999) 0.89
Diagnostic value of molecular forms of prostate-specific antigen for female breast cancer. Clin Biochem (1996) 0.89
Time-resolved delayed luminescence image microscopy using an europium ion chelate complex. Biophys J (1994) 0.89
Molecular characterization of zyme/protease M/neurosin (PRSS9), a hormonally regulated kallikrein-like serine protease. Genomics (1999) 0.89
Expression of the normal epithelial cell-specific 1 (NES1; KLK10) candidate tumour suppressor gene in normal and malignant testicular tissue. Br J Cancer (2001) 0.89
Relapse and cure rates of prostate cancer patients after radical prostatectomy and 5 years of follow-up. Clin Biochem (2000) 0.88
Quantitative analysis of mutant p53 protein in breast tumor cytosols and study of its association with other biochemical prognostic indicators in breast cancer. Breast Cancer Res Treat (1994) 0.88
Immunoenzymatically determined pepsinogen C concentration in breast tumor cytosols: an independent favorable prognostic factor in node-positive patients. Clin Cancer Res (1999) 0.88
Structural characterization and mapping of the normal epithelial cell-specific 1 gene. Biochem Biophys Res Commun (1998) 0.88